Palisade Bio Reports Early Trial Data for PALI-2108 in Crohn’s Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy PALI?
Source: seekingalpha
- Clinical Trial Progress: Palisade Bio reported two weeks of data from its early-stage trial of PALI-2108 for fibrostenotic Crohn’s disease, indicating endoscopic response rates comparable to AbbVie's Skyrizi and Rinvoq, highlighting its therapeutic potential.
- Safety Profile: The therapy showed no serious adverse events among five patients, and the experimental treatment was well tolerated, demonstrating its safety for clinical application.
- Follow-up Research Plans: Palisade Bio intends to launch a Phase 2 study to further evaluate PALI-2108's efficacy in moderate to severe Crohn’s disease patients, reflecting the company's confidence in the drug's future market potential.
- Market Outlook: Palisade Bio is viewed as an undervalued biotech firm with blockbuster drug development potential, leading to optimistic market sentiment regarding its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PALI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PALI
Wall Street analysts forecast PALI stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.400
Low
7.00
Averages
13.00
High
25.00
Current: 2.400
Low
7.00
Averages
13.00
High
25.00
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palisade Bio Schedules Virtual Presentation at Needham Healthcare Conference
- Virtual Presentation Scheduled: Palisade Bio will present virtually at the Needham & Co. 25th Annual Healthcare Conference on April 16, 2026, from 2:15 PM to 2:55 PM ET, showcasing its innovative drug development in inflammatory and fibrotic diseases.
- Management Engagement: CEO JD Finley and CMO Dr. Mitchell Jones will participate in the conference, engaging in one-on-one meetings with registered investors post-presentation, enhancing transparency and interaction with the investment community.
- Product Development Progress: The company's lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon, enabling targeted inhibition at disease sites while improving patient convenience and tolerability.
- Clinical Study Plans: Palisade is advancing towards a Phase 2 clinical study in ulcerative colitis, aimed at evaluating clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission, highlighting its potential in chronic disease treatment.
See More
Palisade Bio Reports Early Trial Data for PALI-2108 in Crohn’s Disease
- Clinical Trial Progress: Palisade Bio reported two weeks of data from its early-stage trial of PALI-2108 for fibrostenotic Crohn’s disease, indicating endoscopic response rates comparable to AbbVie's Skyrizi and Rinvoq, highlighting its therapeutic potential.
- Safety Profile: The therapy showed no serious adverse events among five patients, and the experimental treatment was well tolerated, demonstrating its safety for clinical application.
- Follow-up Research Plans: Palisade Bio intends to launch a Phase 2 study to further evaluate PALI-2108's efficacy in moderate to severe Crohn’s disease patients, reflecting the company's confidence in the drug's future market potential.
- Market Outlook: Palisade Bio is viewed as an undervalued biotech firm with blockbuster drug development potential, leading to optimistic market sentiment regarding its future performance.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics Overview: While specific stock names are not mentioned, such rating changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Investor Focus: For those considering buying ALMS stock, analysts' opinions will serve as a crucial reference point, potentially affecting their buying decisions and overall market sentiment.
- Data Source Note: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions while reminding investors to approach market analyses and recommendations with caution.
See More
Palisade Bio to Participate in Immunology Symposium
- Virtual Fireside Chat: Palisade Bio will participate in the Piper Sandler Virtual Immunology Symposium on February 12, 2026, from 1:30 PM to 1:55 PM ET, featuring CEO JD Finley and CMO Dr. Mitchell Jones discussing the company's innovations in immunology.
- PALI-2108 Drug Development: PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon, aimed at improving pharmacology and tolerability for patients with inflammatory and fibrotic diseases.
- Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics consistent with localized activation.
- Future Research Plans: The company is advancing towards a Phase 2 clinical study for PALI-2108, designed to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission.
See More
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
- Clinical Data Presentation: Palisade Bio's PALI-2108 has been selected for poster presentations at two international inflammatory bowel disease meetings in January and February 2026, showcasing the drug's potential in ulcerative colitis treatment and enhancing the company's reputation in the biopharmaceutical sector.
- Immune Balance Restoration: PALI-2108 rapidly restores immune-epithelial balance in ulcerative colitis patients through gut-targeted PDE4B inhibition, indicating its clinical efficacy and potentially providing new treatment options for patients.
- Successful Clinical Trials: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which strengthens its market competitiveness.
- Future Research Plans: Palisade Bio plans to initiate a Phase 2 clinical study for PALI-2108 in 2026 to evaluate clinical remission and pharmacodynamic biomarkers in ulcerative colitis, further validating its therapeutic effects and expanding its indications.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
Palisade Bio Schedules Virtual Presentation at Needham Healthcare Conference
- Virtual Presentation Scheduled: Palisade Bio will present virtually at the Needham & Co. 25th Annual Healthcare Conference on April 16, 2026, from 2:15 PM to 2:55 PM ET, showcasing its innovative drug development in inflammatory and fibrotic diseases.
- Management Engagement: CEO JD Finley and CMO Dr. Mitchell Jones will participate in the conference, engaging in one-on-one meetings with registered investors post-presentation, enhancing transparency and interaction with the investment community.
- Product Development Progress: The company's lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon, enabling targeted inhibition at disease sites while improving patient convenience and tolerability.
- Clinical Study Plans: Palisade is advancing towards a Phase 2 clinical study in ulcerative colitis, aimed at evaluating clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission, highlighting its potential in chronic disease treatment.
See More
Palisade Bio Reports Early Trial Data for PALI-2108 in Crohn’s Disease
- Clinical Trial Progress: Palisade Bio reported two weeks of data from its early-stage trial of PALI-2108 for fibrostenotic Crohn’s disease, indicating endoscopic response rates comparable to AbbVie's Skyrizi and Rinvoq, highlighting its therapeutic potential.
- Safety Profile: The therapy showed no serious adverse events among five patients, and the experimental treatment was well tolerated, demonstrating its safety for clinical application.
- Follow-up Research Plans: Palisade Bio intends to launch a Phase 2 study to further evaluate PALI-2108's efficacy in moderate to severe Crohn’s disease patients, reflecting the company's confidence in the drug's future market potential.
- Market Outlook: Palisade Bio is viewed as an undervalued biotech firm with blockbuster drug development potential, leading to optimistic market sentiment regarding its future performance.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics Overview: While specific stock names are not mentioned, such rating changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Investor Focus: For those considering buying ALMS stock, analysts' opinions will serve as a crucial reference point, potentially affecting their buying decisions and overall market sentiment.
- Data Source Note: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions while reminding investors to approach market analyses and recommendations with caution.
See More
Palisade Bio to Participate in Immunology Symposium
- Virtual Fireside Chat: Palisade Bio will participate in the Piper Sandler Virtual Immunology Symposium on February 12, 2026, from 1:30 PM to 1:55 PM ET, featuring CEO JD Finley and CMO Dr. Mitchell Jones discussing the company's innovations in immunology.
- PALI-2108 Drug Development: PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon, aimed at improving pharmacology and tolerability for patients with inflammatory and fibrotic diseases.
- Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics consistent with localized activation.
- Future Research Plans: The company is advancing towards a Phase 2 clinical study for PALI-2108, designed to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission.
See More
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
- Clinical Data Presentation: Palisade Bio's PALI-2108 has been selected for poster presentations at two international inflammatory bowel disease meetings in January and February 2026, showcasing the drug's potential in ulcerative colitis treatment and enhancing the company's reputation in the biopharmaceutical sector.
- Immune Balance Restoration: PALI-2108 rapidly restores immune-epithelial balance in ulcerative colitis patients through gut-targeted PDE4B inhibition, indicating its clinical efficacy and potentially providing new treatment options for patients.
- Successful Clinical Trials: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which strengthens its market competitiveness.
- Future Research Plans: Palisade Bio plans to initiate a Phase 2 clinical study for PALI-2108 in 2026 to evaluate clinical remission and pharmacodynamic biomarkers in ulcerative colitis, further validating its therapeutic effects and expanding its indications.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
